Are you Dr. Hasni?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1427 Casino Cir
Silver Spring, MD 20906Phone+1 301-451-1599Fax+1 301-451-5655
Summary
- Dr. Sarfaraz Hasni, MD is a rheumatologist in Silver Spring, Maryland. He is currently licensed to practice medicine in Maryland, New York, and Michigan. He is affiliated with Northwest Hospital.
Education & Training
Stony Brook Medicine/University HospitalFellowship, Rheumatology, 2007 - 2009
Nassau University Medical CenterResidency, Internal Medicine, 1995 - 1998- Nassau University Medical CenterResidency, Pathology-Anatomic and Clinical, 1993 - 1995
Sind Medical CollegeClass of 1993
Certifications & Licensure
MD State Medical License 2022 - 2026
NY State Medical License 2006 - 2026
MI State Medical License 1998 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Clinical Trials
- Study of Systemic Lupus Erythematosus Start of enrollment: 1994 Feb 10
- Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy Volunteers Start of enrollment: 2002 Feb 13
- Monoclonal Antibody Treatment for Systemic Lupus Erythematosus Start of enrollment: 2002 Sep 02
- Join now to see all
Publications & Presentations
PubMed
- 101 citationsLow-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosusSaifur Rahman, Divya Sagar, Richard N. Hanna, Yaíma L. Lightfoot, Pragnesh Mistry
Annals of the Rheumatic Diseases. 2019-07-01 - 1114 citations2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus ErythematosusMartin Aringer, Karen H. Costenbader, David I. Daikh, Ralph Brinks, Marta Mosca
Arthritis & Rheumatology. 2019-09-01 - 110 citationsPhase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosusSarfaraz Hasni, Sarthak Gupta, Michael Davis, Elaine Poncio, Yenealem Temesgen-Oyelakin
Nature Communications. 2021-06-07
Press Mentions
Glitazone Drug May Cut Lupus Heart RiskAugust 4th, 2022- Lupus or Not? Machine Learning May Help Diagnose Lupus EarlyMay 19th, 2021
- Fever, Aches from Pfizer, Moderna Jabs Aren’t Dangerous but May Be Intense for SomeNovember 18th, 2020
- Join now to see all
